Ascendis Pharma A/S (ASND) research

Ascendis Pharma A/S
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$228.03
As of

Kresmion compiles this page from ASND's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Ascendis Pharma A/S (ASND): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-29.

As of . Source: SEC EDGAR filings for ASND. Method and limitations.

SHARE THIS CARD

Share the ASND intelligence card

A branded snapshot of ASND: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ASND intelligence card preview
Post to X
COMPANY DOSSIER

See the full ASND dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for ASND on one page. Preview it with sample data, then open it live with a free account.

Preview the ASND dossier

Active signals for ASND

FREE, NO ACCOUNT

Every signal on ASND, as it fires

You are seeing 5 of 19 signals recorded on ASND since 2026-05-30.

The five above landed across 3 days. The other 14 were recorded on 2 other days. 10 of the 19 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ASND (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP K08588103 · 2026Q2$81.6M0.06%,
MILLENNIUM MANAGEMENT LLCCUSIP K08588103 · 2026Q2$71.1M0.03%,
CITADEL ADVISORS LLCCUSIP K08588103 · 2026Q2$36.8M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP K08588103 · 2026Q2$31.9M0.04%,
D. E. Shaw & Co., Inc.CUSIP K08588103 · 2026Q2$8.2M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ASND

ASND against its peers

ASND's operating margin of -18.9% ranks in the 45th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-01-02.

MetricASNDPeer medianPercentilen
Revenue FY720M EURn/an/a1
Revenue YoY98.0%n/an/a1
Gross margin86.8%n/an/a1
Operating margin-18.9%8.7%4520
Net margin-31.7%-4.3%4020
Return on equityn/a-0.3%n/a19
P / En/a31.4xn/a8

Peers (23): EXEL, NBIX, SMMT, BBIO, HALO, MDGL, BMRN, GMAB, APGE, KRYS, NUVL, UTHR, INCY, INSM, BNTX, PTGX, KYMR, CYTK, ARWR, IBRX, CRNX, CAI, RPRX. Left out: SBMFF (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-01-02. Every figure is one full fiscal year read from one annual filing (ASND: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Follow ASND on a live board

Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ASND for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the ASND dossier